Mostrando 2 resultados de: 2
Subtipo de publicación
Article(2)
Área de conocimiento
Inmunología(2)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(2)
ODS 3: Salud y bienestar(2)
ODS 9: Industria, innovación e infraestructura(2)
Origen
scopus(2)
Immunological evaluation of rheumatoid arthritis patients treated with itolizumab
ArticleAbstract: Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation that affects approPalabras claves:Anti-idiotypic antibody response, Itolizumab, Peripheral lymphocytic counts, Proinflammatory cytokines, Rheumatoid ArthritisAutores:Aira L.E., Carmen Elena Viada, Chico A., Fuentes K.P., Gómez J.A., Gonzalez Z., Hernández P., Mazorra Z., Prada D.M.Fuentes:scopusThe anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
ArticleAbstract: Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging rPalabras claves:CD6, Clinical trial, Itolizumab, Phase I, Rheumatoid ArthritisAutores:Aira L.E., Ávila Y., Barrese Y., Carmen Elena Viada, Gómez J.A., Hernández I.M., Hernández M.V., Hernández P., López A.M., Martínez J.P., Milera J.M., Molinero C., Montero E., Moreno E., Prada D.M., Reyes Y., Rodríguez P.C., Torres R.Fuentes:scopus